Criteria
Age ≥ 18 years
Men and transgender persons who have sex with changing male partners and/or transgender persons (per STIKO recommendation)
"Patient treated at participating study centre for minimum 6 months prior to July 1, 2022 (≥1 contact between Jan 1, 2021 and Dec 31, 2021)"
"≥1 contact with study centre after end of follow-up (Q4/2022, Q1/2023, Q2/2023, or Q3/2023)"
Subjects aged ≥65 years on day of vaccination
No influenza vaccination history before beginning of trial
Adults aged 18 years or older
with evidence of a COVID-19 primary series vaccination (two mRNA vaccinations from the same manufacturer [Pfizer-BioNTech or Moderna] or one Ad26.COV2.S vaccination) administered between 1 January 2021 and 6 July 2022
with at least 365 days of medical and pharmacy pre-index enrollment were eligible for the study cohorts
older adults who survived and were at least 65 years old at the start of the 36th week in 2017 and 2018
Age ≥18 years
Continuous medical and pharmacy claims enrollment
"At least one lab test, closed medical claim, or closed pharmacy claim in the 365 days prior to cohort entry"
"Received single dose of Ad26.COV2.S between March 1, 2021 and July 31, 2022 (exposed group)"
individuals who received at least one influenza vaccine or an influenza and COVID vaccine on the same day during the identification period.
participants aged 64 years and older
individuals receiving their first PPV23 dose in the months leading up to their 65th birthday
"older adult individuals who were either concomitantly vaccinated with PPSV-23 and influenza vaccines, or received the influenza vaccine (which is recommended annually for older adults) before getting the PPSV-23 vaccine sequentially"
"Participants were adult recipients of solid organ transplants, encompassing renal, hepatic, cardiac, and pulmonary grafts, prior to the detection event."
Age ≥2 months at cohort entry or registered in SIP and followed during RV seasons (Nov–Apr)
patients ≥ 18 years of age
"consecutively admitted to the ICU between January 1, 2021 and September 1, 2022 because of COVID-19–related ARF."
aged 18 years or older
with a diagnosis of COVID-19 confirmed
COVID-19 as the primary diagnosis.
Age >= 18 years
Massachusetts resident
">=2 instances of a SARD ICD-9 or ICD-10 code within 2 years of 3rd dose of vaccine, one within the previous 12 months, Prescription or administration of csDMARD, bDMARD, tsDMARD within 12 months of 3rd mRNA vaccination, or a prescription for a minimum of 30 pills of either prednisone or methylprednisolone within 6 months of 3rd mRNA vaccination"
Eligible to receive 4th mRNA COVID vaccination between 16/Jan/2022 11/Jun/2022
aged ≥ 18 years
resided in NYC
met criteria for having had a high-risk or intermediate-risk exposure to a person with confirmed or probable mpox disease
age 5–11 years for children or 12–20 years for adolescents at the start of the study period
no previous COVID-19 vaccination
no documented SARS-CoV-2 infection
prior encounter (including telephone or telehealth) within 18 months
COVID-19 patients with solitary solid malignancy
patients aged ≥18 years consecutively hospitalized at MHS
alive on 8 December 2020
"residents (as of April) who would turn 65, 70, 75, 80, 85, 90, or 95 years of age by the next March"
at least 1 year of residency
adult patients hospitalized for moderate or severe COVID-19
"treated at Infectious and Tropical Diseases Department in a third-level (1,600-bed) center"
"hospitalization between September 1, 2020 and January 31, 2022"
received remdesivir 200 mg on day 1 followed by 100 mg/day for 4 days
required supplemental oxygen via nasal cannula
had radiographic evidence of interstitial pneumonia
patients with cancer diagnosed (current or previous history of invasive cancer)
diagnosed with COVID-19 in 2021 or 2022
laboratory-confirmed SARS-CoV-2 infection
patients with NMOSD who fulfilled the 2015 IPND criteria
patients with MS who fulfilled the McDonald 2017 criteria
no prior COVID-19 infection
no previous exposure to other COVID-19 vaccines
at least 365 days of prior observation
primarily resided in New York City according to zip code
VA enrollees aged ≥18 years
"alive as of December 11, 2020"
had inpatient or outpatient encounter in VA in preceding 12 months
"received at least one dose of BNT162b2 or mRNA-1273 between December 11, 2020 and March 25, 2021"
singleton live births with mother–offspring linkage in the health fund
gestations with last menstruation date ≥42 weeks before study end for birth outcomes
alive and ≥65 on 11/01/2017
continuously enrolled in Part D ≥12 months prior
enrolled in Parts A & B (not Part C) ≥15 months prior
community-dwelling (not in nursing home/SNF/hospice) on index date
Age ≥18 on index date
continuous medical and pharmacy enrollment with ≤45-day gaps from 365 days pre-index through cohort entry date (CED)
≥1 medical or pharmacy claim in baseline 365 days.
Age ≥60 years as of trial month start
Engaged in VHA care (primary care encounter within 18 months)
Known residential address (ZIP code)
aged ≥ 18 years on the index date
had continuous enrollment in medical or pharmacy plans during a 365-day baseline period prior to and including index date
"had evidence of having received three doses of mRNA-based COVID-19, the first dose being on or after December 11, 2020"
"The required window between the first and second dose was determined by the combination of the first two doses: 28 ± 5 days for homologous two doses of mRNA-1273, 21 ± 5 days for homologous two doses of BNT162b2, and 28 ± 5 days for heterologous two doses"
The third dose must have been received at least 42 days after the second dose. In addition
individuals had to be identified as IC
resided in a VA nursing home for at least 100 days
non-resident gap no more than ten days
received primary SARS-CoV-2 vaccination series
aged 40 years or more
"previously vaccinated with a two-dose homologous primary vaccination scheme of the most common combinations: CoronaVac (Cov), ChAdOx1 (Az) or BNT162b2 (Pf)"
who received the first booster dose with any vaccine
were alive and eligible to the second booster.
Age 18–85 years
received at least one dose of ChAdOx1 or an mRNA-based vaccine (BNT162b2 or mRNA-1273)between 1 April 2021 and 30 September 2021
identifiable in NHIS database.
Veteran aged ≥18 years
No prior COVID-19 vaccination
"At least one outpatient, inpatient, or pharmacy encounter in prior year"
Enrolled for at least 1 year in VHA
residents aged ≥65 years on index date
"continuously enrolled in Medicare Parts A/B Fee-for-Service (FFS) from April 1, 2020 through index date with no Part C enrollment"
"residing in a nursing home since December 13, 2020 and until index date"
had a MDS assessment 183 days prior to index date
resided in a nursing home with available data in NHC and census tract information on COVID-19 circulation
resided in nursing homes where over 10% of residents had at least one observed vaccine administration code on or before March 1st
residents with fewer than three COVID-19 vaccine administrations were excluded if administration codes indicated a second or third dose without a preceding dose observed
patients required to have 1 inpatient or 2 outpatient billing codes ≥30 and ≤365 days apart
had at least 1 year and up to 5 years of continuous enrollment in a fee-for-service insurance plan with prescription drug coverage
no GD billing codes present
aged ≥75 years
prioritized for vaccination according to the UK Government’s Priority Groups for vaccination
no previous record of COVID-19 [diagnosis/positive polymerase chain reaction (PCR) test
no previous COVID-19 vaccination
with data availability for ≥180days before study start (4 January 2021)] were included to the source population.
Aged ≥15 years
insured with AOK Baden-Württemberg
residence in Baden-Württemberg
had to be insured from January 2013 until December 2014.
individuals between 18 to 89 years of age
"who received their first covid vaccination with either of these two vaccines from January 1, 2021, to August 31, 2021"
at least two years of continuous enrolment with a general practice prior to entering the study
documented receipt of all FDA-authorized doses of the initial mRNA vaccination series
"documented receipt of a third dose between July 1, 2021 and April 29, 2022"
had a primary care visit at a VHA facility in 2019 or 2020
aged 2–6 years
continuous residency in Denmark for one year prior to inclusion
no prior influenza vaccination
no contraindication for LAIV-4
previously participated in the Danish childhood vaccination program
Age ≥60 years
in municipal databases
vaccinated with CoronaVac between 2021-01-21 and 2021-08-31 or eligible as unvaccinated match at rollout
"available baseline covariates (age, sex, neighborhood HDI)."
adults aged 18–64 years
recorded receipt of IIV4c or IIV4e during the 2019–2020 US influenza season
at least 1 year of primary care medical history in the Veradigm EMR dataset
continuous enrollment in the Komodo claims data for 6 months before the vaccination date and after the end of the primary observation period
Births at ≥20 weeks' gestation from 07/01/2021 to 03/31/2022 for sociodemographic analyses
"for perinatal outcome comparisons, women whose gestational weeks 20–43 fell entirely within the 9-month data collection period"
primary outcome analyses restricted to singleton pregnancies ≥24 weeks after excluding congenital anomalies
Received at least two COVID-19 mRNA vaccine doses on/after 01/05/2021
"recorded in national databases for COVID-19 laboratory testing, vaccination, hospitalisation, and death."
"received a third dose of BNT162b2 or mRNA-1273 between October 29, 2021 and February 25, 2022"
aged ≥18 years
registered at a general practice using TPP’s SystmOne clinical information system at the time of boosting
received a two-dose primary vaccination course of either BNT162b2 or ChAdOx1-S
received second dose of an mRNA vaccine primary series at least 6 months earlier
known residential address outside of a long-term care facility
known smoking status within the previous year
known body-mass index within the previous year
used the VA healthcare system during the previous year (received care at an eligible station and had at least one primary care visit)
no healthcare visit within the previous 3 days (to avoid inclusion of symptomatic disease onset)
people aged ≥50 years
received at least three doses of COVID-19 vaccine (primary course and first booster)
"individuals surviving infection-free with ≥2 doses between December 11, 2020 and April 30, 2021"
"no prior record of a booster dose of BNT162b2 or mRNA-1273 before September 22, 2022 (FDA emergency use approval date for third dose)"
residents present in nursing home for at least 100 days with a gap of no more than 10 days
received a 2-dose mRNA vaccine series at least 120 days earlier
aged ≥18 years
"alive as of December 1, 2021"
received exactly 2 doses of mRNA vaccination
aged ≥ 18 years
received 2 doses of mRNA-1273 or BNT162b2
continuously enrolled in a medical and pharmacy plan for 365 days before the index date were included
Immunocompromised individuals were identified as those meeting at least one of the following criteria: (evidence of blood or stem cell transplant 2 years before the index date
history of organ transplant and taking immunosuppressive therapy 60 days before the index date
evidence of active cancer treatment 180 days before the index date with an active cancer diagnosis in the year before treatment
any history of primary immunodeficiency disorder
or any history of HIV.)
at least 2 instances of a rheumatic disease ICD-9 or ICD-10 code within 2 years of the index date (one within the previous 12 months)
"prescription or administration of a csDMARD, bDMARD, or tsDMARD within 12 months of the index date and/or prescription for at least 30 pills of prednisone or methylprednisolone within 6 months of the index date"
received at least 2 doses of BNT162b2 or at least 2 doses of mRNA-1273
adults aged ≥18 years at date of first dose vaccination
registered in any contributing database
received at least one dose of a COVID-19 vaccine during the study period
had at least one year of history available in the database before the index vaccination date
had complete records for age and sex
"MHS members with positive SARS-CoV-2 PCR test result by December 2, 2020"
"not previously vaccinated before March 2, 2021"
eligible for one dose of BNT162b2 vaccine after at least 3 months from infection per Israeli Ministry of Health guidelines
"aged ≥16 years by March 2, 2021"
patients who underwent a surgical procedure at any VA facility nationwide
vaccination group received two doses of COVID-19 vaccine at least two weeks before surgery
"health and social care workers vaccinated between January 4 and February 28, 2021"
aged 18–64 years inclusive
received either vaccine during the 56-day period when both were widely administered
"information available on sex, ethnicity, deprivation, and geographical region"
resident in Denmark
linked across national registers
"follow-up from age 11 or January 1, 2007"
"infants born at 4 health facilities between May 28 and December 31, 2015, and between April 15 and December 31, 2016"
adults aged ≥18 years diagnosed with COVID-19
female aged 25–65 years
underwent CO₂ laser ablation for CIN1 or LEEP for CIN2-3
signed informed consent
aged 40–85 years
tested positive for SARS-CoV-2 between April 2021 and May 2022
students participating in the testing program
aged 5–11 years and 12 years and older
aged 50 years (eligible for RZV per Advisory Committee on Immunization Practices recommendations)
continuously enrolled in OLDW for at least 365 days
"from January 1 to December 31, 2018, included all patients aged ≥50 years"
"from January 1 to December 31, 2019, included only patients who turned 50 years of age"
"aged >18 years between July 1, 2020 and July 6, 2022"
had a primary care visit at a VHA facility between 2020 and 2022
documented receipt of all FDA-authorized doses of the initial mRNA vaccination series
"documented receipt of at least one booster dose before September 1, 2022"
VA enrollees aged ≥18 years
assigned to a VA primary care team in the prior 18 months
known residential address and VISN assignment
received at least one documented COVID-19 vaccine in the VA healthcare system at any time
aged ≥65 years
"residency in Denmark, Finland, or Sweden (to ensure linkable identifier)"
no previous hospital admissions for COVID-19
received ≥4 doses of COVID-19 vaccines
"men aged ≥18 years as of June 12, 2022"
"at least one proxy for risk of exposure to mpox (one syphilis test in the previous year, a new bacterial STI diagnosis in the previous year, or a filled prescription for HIV pre-exposure prophylaxis in the previous year)"
individuals aged ≥12 years
"received a 2-dose or 3-dose vaccine with the same brand between January 1, 2022 and December 31, 2022"
aged ≥5 years
"received at least one dose of an mRNA COVID-19 vaccine between December 13, 2020 and March 16, 2022 in Georgia, US"
eligibility defined as unvaccinated individuals with one documented infection at least 90 days earlier
eligible during a 1-week enrollment period to receive a single dose of BNT162b2 vaccine or remain unvaccinated
participants allocated to vaccinated or unvaccinated group accordingly
adult patients aged >18 years
self-reported long COVID with at least one of 53 listed symptoms persisting >3 weeks after initial infection and ≥1 symptom at baseline
confirmed or suspected prior SARS-CoV-2 infection
"documented primary SARS-CoV-2 infection in Qatar between February 28, 2020 and May 12, 2022"
no vaccination record before the start of follow-up (natural infection cohort)
"received at least two doses of the same vaccine (BNT162b2 or mRNA-1273) between January 5, 2021 and May 12, 2022"
no previous documented infection
no booster vaccination before the start of follow-up (vaccinated cohort)
children aged 5–11 years and adolescents aged 12–17 years
at least 14 days after receipt of the second BNT162b2 vaccine dose
completed two-dose BNT162b2 primary series (vaccinated cohort)
national control cohort included previously uninfected and unvaccinated persons (control cohort)
"aged ≥18 years between January 4, 2021 and May 14, 2021"
no previously documented positive SARS-CoV-2 PCR test
no healthcare interactions within past 3 days
no previous COVID-19 vaccination
"no contraindications for COVID-19 vaccination (severe or immediate allergic reaction to vaccine, its components, or polysorbate)"
known residential address
not residing in a long-term care facility
user of VA healthcare system (care at eligible station and ≥1 in-person or telehealth primary care visit in past year)
known smoking status and BMI in the past year
"at least 6 weeks of potential follow-up before July 1, 2021"
aged ≥18 years
"alive as of December 11, 2020 (date of emergency use authorization for BNT162b2)"
"had inpatient or outpatient encounter in VA healthcare system in preceding 12 months or until March 26, 2021"
received at least three doses of SARS-CoV-2 vaccine
no documented SARS-CoV-2 infection prior to index date
